This means the FDA (the US drug regulator) would make it official rule: if you're running a federally funded psychedelic study, you must screen people to see if they take fluoxetine. If that interaction is real and dangerous, the FDA will probably make this a rule — but that takes time, and it won't happen until the evidence is really solid.
Separated from the replication count claim for independent falsifiability. FDA or NIH establishing DDI screening as a required element in trial protocols is a distinct institutional action from publication counts. If replication studies confirm the interaction, protocol guidance typically follows within 12-24 months. However, 'required screening criterion' implies formal guidance or protocol amendment — a higher bar than informal best practice. Conditional on meaningful replication occurring, probability is moderate-high. Unconditionally, lower. Set at 0.52.